Patent · US Active

Method of treating factor IX deficiency using nuclease-mediated targeted integration

US10370680B2 · kind B2 · utility

0Cited by
40References
3Claims
0Family size

Assignee

Inventors

Key dates

Filing dateFeb 24, 2015
Grant dateAug 6, 2019
Priority date—
Expiry dateMay 15, 2035

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2750/14141
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

Disclosed herein are methods and compositions for targeted, nuclease-mediated insertion of transgene sequences into the genome of a cell.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.